1. Home
  2. KNOP vs IPHA Comparison

KNOP vs IPHA Comparison

Compare KNOP & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KNOT Offshore Partners LP

KNOP

KNOT Offshore Partners LP

HOLD

Current Price

$11.45

Market Cap

370.1M

ML Signal

HOLD

Logo Innate Pharma S.A. ADS

IPHA

Innate Pharma S.A. ADS

HOLD

Current Price

$2.22

Market Cap

189.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KNOP
IPHA
Founded
2013
1999
Country
United Kingdom
France
Employees
874
163
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
370.1M
189.5M
IPO Year
2012
N/A

Fundamental Metrics

Financial Performance
Metric
KNOP
IPHA
Price
$11.45
$2.22
Analyst Decision
Hold
Strong Buy
Analyst Count
1
4
Target Price
N/A
$5.75
AVG Volume (30 Days)
82.3K
126.4K
Earning Date
05-19-2026
03-26-2026
Dividend Yield
1.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$3.51
$180.36
Revenue Next Year
N/A
N/A
P/E Ratio
$9.00
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.16
$1.18
52 Week High
$11.55
$2.63

Technical Indicators

Market Signals
Indicator
KNOP
IPHA
Relative Strength Index (RSI) 64.09 65.66
Support Level $10.04 $1.72
Resistance Level $11.55 $2.34
Average True Range (ATR) 0.32 0.20
MACD 0.01 0.09
Stochastic Oscillator 89.01 68.85

Price Performance

Historical Comparison
KNOP
IPHA

About KNOP KNOT Offshore Partners LP

KNOT Offshore Partners LP owns, operates, and shuttles tankers under long-term charters in the North Sea and Brazil. The company provides crude oil loading, transportation, and storage services under time charters and bareboat charters. The Partnership is formed for acquiring ownership interests in over four shuttle tankers owned by Knutsen NYK Offshore Tankers AS (KNOT). It operates through the shuttle tanker market segment.

About IPHA Innate Pharma S.A. ADS

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.

Share on Social Networks: